Related Experiment Videos
[Multiple myeloma--new therapeutic perspectives].
A B Skotnicki1, T Wolska-Smoleń, A Jurczyszyn
1Kliniki Hematologii Collegium Medicum, Uniwersytetu Jagiellońskiego w Krakowie. alekskot@endo.cm-uj.krakow.pl
Przeglad Lekarski
|September 24, 1999
Summary
High-dose chemotherapy with stem cell transplantation is the leading treatment for multiple myeloma. Blood stem cells are preferred for financial and hematological benefits, despite risks like chromosomal aberrations.
Area of Science:
- Hematology
- Oncology
Context:
- Multiple myeloma treatment landscape.
- Bone marrow transplantation centers data.
Purpose:
- Summarize current best practices for multiple myeloma treatment.
- Identify key risk factors and optimal stem cell sources.
Summary:
- High-dose chemotherapy and stem cell transplantation represent the current standard of care for multiple myeloma.
- Risk factors include chromosomal aberrations and elevated serum levels of beta-2-microglobulin, C-reactive protein (CRP), and lactate dehydrogenase (LDH).
- Peripheral blood stem cells are recommended as the optimal source due to economic and hematological advantages.
Impact:
- Provides insights into multiple myeloma management.
- Highlights prognostic indicators for patient outcomes.
- Informs clinical decisions regarding stem cell sourcing.